# A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is

> **NCT03835481** · PHASE2 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 165 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** BI 730357
- **DRUG:** Placebo to match BI 730357

## Key facts

- **NCT ID:** NCT03835481
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-18
- **Primary completion:** 2021-06-22
- **Final completion:** 2021-07-27
- **Target enrollment:** 165 (ACTUAL)
- **Why stopped:** Due to company decision.
- **Last updated:** 2022-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03835481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03835481, "A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03835481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*